Efficacy of Anti-Epileptic Medications for Angelman Syndrome T. J. Bichell, V. Kimonis, E. Sanborn, C. Bacino, A. Beaudet, L. Bird, M. Nespeca
The world is full of obvious things which nobody by any chance ever observes. --Sherlock Holmes
Folic Acid/Betaine Study Conducted from 21-26 N = 62 Four visits Parent Interviews Medical Histories Physical Examinations Geneticists, Neurologists EEG s
History of Seizures and Deletion Status 6 5 9 Number of Patients 4 3 2 45 Non-Deletion Deletion 1 History of Seizures 3 5 No Hx of Seizures
Age at Entry into Folic Acid/Betaine Study Average Age in Months 8 7 6 5 4 3 2 1 Deletion Non-Deletion All Subjects History of Seizures No Hx of Seizures Angelman Syndrome Deletion Status
History of Seizures in Non-Deletion Subjects 6 Number of Subjects 5 4 3 2 1 UPD Ube3a ICM Unknown Non-Deletion Hx Sz No Hx Genetic Diagnosis of Angelman Syndrome
Pre-Study Folate Levels Blood Folate Levels 9 8 7 6 5 4 3 2 1 Hx Seizures No Hx Deletion Non-Deletion Deletion Status and History of Seizures
Effect of Study Medicine Onset of Seizures Related to Drug/Placebo Number of Subjects 5 45 4 35 3 25 2 15 1 5 Sz Prior Began Sz On Drug Began Sz On Placebo No Seizures Non-Deletion Deletion
Subjects without Seizure History 9 of 62 subjects, younger at entry to study Pre-Study blood folate levels higher 4 are Ube3a, of which 3 are on Keppra 1 is ICM 2 are Class 1 Deletion, 1 on Depakote 3 are Class 2 Deletion
Definition of Effectiveness Seizure-free at time of follow-up interview for at least 6 months. Many had been seizure-free for much longer than 6 months Note: some had visible absence seizures but parents had reported them to be seizure-free
Anti-Epileptics Used Singly Depakote or Depakene/divalproex sodium or valproate sodium 8/15 = 53% Gabitril/tiagabine hydrochloride /1= % Keppra/levetiracetam 3/3 = 1% Klonopin/clonazepam 6/6 = 1% Phenobarb/phenobarbital 2/1 = 2% Tegretol/carbamazepine /3 = % Topamax/topiramate 2/7 = 29% Tranxene/clorazepate dipotassium 1/1= 1%
Effectiveness of Anti-Epileptics Used as a Single Drug in Angelman Syndrome Number Controlled 1 8 6 4 2-2 -4-6 -8-1 carb/teg clon/klo valp/dep leve/kep phen/phe topi/top Uncontrolled as a Single Med Controlled as Single Anti-Epileptic
Anti-Epileptics Used in Combinations Ativan/lorazepam 2/2 1% Depakote or Depakene/divalproex sodium or valproate sodium1/19 53% Dilantin/phenytoin1/1 1% Kepra/levetiracetam 2/3 66% Klonopin/clonazepam 9/12 75% Lamictal/lamotrigine 3/6 5% Phenobarb/phenobarbital 1/4 25% Tegretol/carbamazepine /1 % Topamax/topiramate 7/12 58% Zarontin/ethosuximide 1/3 3% Zonigran/zonisamide 3/3 1%
15 1 5-5 -1 Effectiveness of Anti-Epileptics Used in Combination for Angelman Syndrome Non-Del-Unc Non-Del Cont Del Uncont Deletion Cont D/v combo D/P combo K/L combo K/C combo L/L combo P/P combo T/C combo T/T combo Z combo Z/Z combo Medications Used A/l combo Number Controlled
Effectiveness of Anti-Epileptics in Angelman Syndrome (used in 3 or more patients) % Controlled 1% 8% 6% 4% 2% % -2% -4% -6% -8% -1% 9 2 3 1 3 3 7 6 1 8 2 2-3 -7-1 -5-3 -9-3 -8-5 -3-1 carb/teg clon/klo valp/dep lamo/lam leve/kep phen/phe topi/top zoni/zon Uncontrolled in Combination -1-3 -9-3 -1-3 -5 Uncontrolled as Single -3-7 -8-5 Controlled in Combination 9 1 3 2 1 7 3 Controlled as Single 6 8 3 2 2 Anti-Epileptic Used
Prior Published Studies of Anti-Epileptics for Angelman Syndrome Viani et al, J. Child Neurology 1995 n=18 in all of our patients isolated seizures and myoclonic status epilepticus were controlled by sodium valproate or combined with clobazam seizures were increased by carbamazepine Ruggieri, M. Arch Dis Child 1998 n=78 Clonazepam and lamotrigene best seizure control and least side effects, valproate next best. Carbamazepine worst, with vigabatrin and phenobarbitol almost as bad. Ostergaard, J. Dev Med Child Neurology 21, n=2 Benzodiazepines, valproate work well, while oxcarbazepine, carbamazepine, vigabatrin often worsen seizures.
Ruggieri, 1998: Parent Questionnaire Study: N=78 +2 +3 +4 +4 4 NTZ +3 +6 +19 +17 23 CLZ +1 +4 +2 +2 5 CLB -3-8 -3-3 9 VGB +5 +4 +7 +12 13 LTG -3-2 -1 6 ESM -1-2 +1 5 PHT -2-1 5 PB -9-13 -13-14 22 CBZ -4-2 +15 +22 45 VPA Behavior Alertness SzSeverity #Sz #pts Drug
Prior Published Studies of Anti-Epileptics for Angelman Syndrome Nolt, D. Am J Health Syst Pharm 23, N = 85 Clobazam and zonisamide best for sz and behavior but few subjects, Clonazepam and valproate next. Carbamazepine worst for sz and behavior. Galvan-Manso,M. Epileptic Disorders 25 Clonazepam 1% positive response, valproate 8% controlled, phenobarb only 3% controlled. Carbamazepine and vigabatrin worst Valente M. et al, Arch Neurol 26. Good therapeutic response to valproic acid, phenobarbital and clonazepam. Detrimental effects from vigabatrin, carbamazepine and oxcarbazepine. Dion, M. et al, Epilepsia 27. Lamotrigen is efficacious as adjunctive therapy
Nolt, et al, 23: Monotherapy Drug Sz Frequency Sz Severity Behavior VPA 2.1 (45) 2.2 (42) 2.9 (44) CBZ 4 (27) 3.7 (27) 4 (27) TPM 3.1 (2) 2.8 (2) 2.9 (19) PB 2.8 (18) 2.6 (18) 3.7 (18) LTG 2.6 (18) 2.4 (18) 2.2 (18) CLZ 1.9 (13) 2.2 (13) 3.9 (14) ESM 2.6 (7) 2.4 (7) 3 (7) CLB 1 (5) 1 (5) 2 (5) ZSM 1.7 (3) 1.7 (3) 2.7 (3)
Nolt, et al, 23: Polytherapy Drugs Sz Frequency Sz Severity Behavior VPA,CLZ 2.8 (6) 2.7 (6) 4.4 (6) VPA, TPM 3.8 (4) 3.8 (4) 3 (4) VPA, TPM, CLZ 3.3 (4) 2.8 (4) 3.3 (4) VPA,LTG 2.8 (4) 3 (4) 1.6 (4) PHT,CBZ 3.5 (4) 3.8 (4) 3.3 (4)
Meta-Analysis of Efficacy of Anti-Epileptics in Angelman Syndrome (used in 3 or more patients) Includes Studies by: Bichell, Schlanger, Dion, Valente, Galvan-Manso (with Galvan derived from percentages) % Controlled 1% 5% % -5% -1% 2-12 -9 carb/te G 5-2 -6 clob/cl O 28 36 15 18-3 -11-2 -22 clon/kl O valp/de P 8 1-3 -3-6 etho/za R lamo/la M 2 3-1 leve/ke P Anti-Epileptic Used 11 2 7 2 2-16 -7-3 -21-8 phen/p HE phtn/di L topi/to P 3 Uncontrolled in Combination -9-6 -11-22 -3-6 -1-21 -3-8 Uncontrolled as a Single Med -12-2 -3-2 -3-16 -7-3 Controlled in Combination 5 28 36 1 8 2 11 2 7 3 Controlled as a Single Med 2 15 18 3 2 2-3 viga/sa B zoni/zo N
Parent Questionnaire Study: Effectiveness of AED s N=78 +2 +3 +4 +4 4 NTZ +3 +6 +19 +17 23 CLZ +1 +4 +2 +2 5 CLB -3-8 -3-3 9 VGB +5 +4 +7 +12 13 LTG -3-2 -1 6 ESM -1-2 +1 5 PHT -2-1 5 PB -9-13 -13-14 22 CBZ -4-2 +15 +22 45 VPA Behavior Alertness SzSeverity #Sz #pts Drug
Case Reports Topiramate: 5 patients, 2 sz free, 2 9% reduction, 1 insomnia/akathisia, Franz, D., Neurology 2 Ethosuximide: 2 patients treated with high doses attained complete remission along with EEG improvement, Sugiura,C. et al, Neurology 21 Levodopa: 2 patients, both improved in motor function and seizures, reduced anti-epileptics. Harbord, M., J. Clin Neurosci 21. Ketogenic diet: 4 refractory patients, all improved, Valente, M. et al, Arch Neurol 26. Omega-3 Fatty Acids: 1 refractory AS patient on topamax and valproate improved greatly with incorporation of omega-3 polyunsaturated fatty acids, Schlanger, S., Epilepsia 22
Oxcarbazepine Topiramate Levetiracetam Ethosuximide Anti-Epileptics in Angelman Syndrome: Summary of the Recommendations Clonazepam Valproate Carbamazapime Lamotrigen Phenobarbitol Vigabatrin Clobazam 2, Zonisamide 1
Recommendations Remember Clonazepam: It works for AS! Avoid: carbamazepine, phenobarbitol, topiramate, trileptal, vigabatrin Potential, need more data: levetiracetam, zonisamide, ethosuximide, ketogenic diet
Types of Seizures Did not have standardized descriptions at different sites Many absence, febrile, partial tonic-clonic, atonic, myoclonic Need long-term follow-up for efficacy and side-effects (all studies are too short-term)
Conclusions GABAR3 deletion may be crucial factor in clonazepam efficacy Different meds for deletion vs. non-deletion AS patients Need more data on deletion class vs. med Treat syndrome, not just seizure type Promising but unstudied: levetiracetam, zonisamide, ethosuximide, ketogenic diet, levodopa, omega-3 fatty acids, vaso-vagal stimulator Look for Thiele, E. et al results of ASF parent survey, reporting at this conference
Acknowledgements David Bichell, MD, San Diego and Nashville Mark Nespeca, MD, San Diego Lynne Bird, MD, San Diego Jenny Chang, Pre-MD, San Diego Beth Hochman, Pre-MD, Boston Virginia Kimonis, MD, Boston Erica Sanborn, Boston Carlos Bacino, MD, Houston Art Beaudet, MD, Houston Lina Shinawi, Houston
Acknowledgements Angelman Syndrome Foundation, Western Area Chapter